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A B S T R A C T
Omeprazole, a proton pump inhibitor used to treat peptic ulcer and gastroesophageal reflux disease, has been
associated to chronic kidney disease and acute interstitial nephritis. However, whether omeprazole is toxic to
renal cells is unknown. Omeprazole has a lethal effect over some cancer cells, and cell death is a key process in
kidney disease. Thus, we evaluated the potential lethal effect of omeprazole over tubular cells.
Omeprazole induced dose-dependent cell death in human and murine proximal tubular cell lines and in
human primary proximal tubular cell cultures. Increased cell death was observed at the high concentrations used
in cancer cell studies and also at lower concentrations similar to those in peptic ulcer patient serum. Cell death
induced by omeprazole had features of necrosis such as annexin V/7-AAD staining, LDH release, vacuolization
and irregular chromatin condensation. Weak activation of caspase-3 was observed but inhibitors of caspases
(zVAD), necroptosis (Necrostatin-1) or ferroptosis (Ferrostatin-1) did not prevent omeprazole-induced death.
However, omeprazole promoted a strong oxidative stress response affecting mitochondria and lysosomes and the
antioxidant N-acetyl-cysteine reduced oxidative stress and cell death. By contrast, iron overload increased cell
death. An adaptive increase in the antiapoptotic protein BclxL failed to protect cells. In mice, parenteral ome-
prazole increased tubular cell death and the expression of NGAL and HO-1, markers of renal injury and oxidative
stress, respectively.
In conclusion, omeprazole nephrotoxicity may be related to induction of oxidative stress and renal tubular
cell death.
1. Introduction
The incidence of acute kidney injury (AKI) is approximately
2000–3000 per million population per year [1]. AKI patients have a
higher risk of developing chronic kidney disease (CKD) and end-stage
renal disease (ESRD) [2]. CKD is present in 10% of the adult population
and is associated with an increased risk of AKI and premature mortality
[3]. AKI implies an abrupt decline in renal excretory function char-
acterized by a reversible increase in the blood concentration of creati-
nine and other molecules, often associated with a decreased urine
output [4,5]. Despite frequent recovery of renal function, mortality
remains high, and even a short-timed injury contributes to a higher
mortality [6]. Tubular cell death is a common features of both AKI and
CKD, eventually leading to tubulointerstitial fibrosis and progressive
nephron loss [6]. Both apoptosis and different pathways of regulated
necrosis, such as necroptosis or ferroptosis, may contribute to tubular
cell death [7–10].
Omeprazole is a proton pump inhibitor (PPI) prescribed to patients
with gastroesophageal reflux disease and peptic ulcer. PPIs are among
the most commonly prescribed drugs, although in a significant per-
centage of patients the prescription is not justified and self-medication
is common [11]. PPIs inhibit the H+/Na+ ATPase in gastric cells, thus
decreasing proton secretion into the gastric lumen. Additionally, they
also inhibit vacuolar ATPase (V-ATPase), and may have anti-
proliferative actions in tumor cells [12,13]. Thus, omeprazole inhibits
pancreatic cancer cell growth [12,13], and promotes apoptosis in
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human melanoma cells and in B-cell malignancies [12,14]. Omeprazole
is a cause AKI due to acute tubulointerstitial nephritis (AIN), especially
in the elderly [15–19]. Additionally, two recent independent studies
associated PPI consumption to an excess risk for CKD [20–23], and a
recent prospective, double-blinded cohort study disclosed that ome-
prazole prophylaxis was associated to increased serum creatinine
among patients admitted to hospital [24]. However, the cellular and
molecular mechanisms of PPI nephrotoxicity in general and specifically
of omeprazole, have not been characterized, thus hampering prevention
and therapy efforts.
2. Methods
2.1. Cell and reagents
Three types of cells were studied, human (HK-2) [25] and murine
(MCT) [26] immortalized proximal tubular epithelial cell lines, and
primary human proximal tubular cell cultures (RPTEC, Cambrex, East
Rutherford, NJ, USA). HK-2 cells were grown in RPMI 1640 (GIBCO),
10% decomplemented fetal bovine serum (FBS), 1% glutamine, 100 U/
mL penicillin, 100 μg/mL streptomycin, 5 μg/mL Insulin Transferrin
Selenium (ITS) and 36 ng/mL hydrocortisone in 5% CO2 at 37 °C. MCTs
were grown in RPMI 1640, 10% FBS, 100 μg/mL streptomycin, 2 mM
glutamine and 100 U/mL penicillin. RPTEC were grown in REGM (renal
epithelial cell growth medium; GIBCO). At 60–70% of confluence, cells
were growth-arrested in serum-free medium for 24 h before the ex-
periments.
Omeprazole (Selleckchem, Munich, Germany) was dissolved in
DMSO and stored at −80 °C. Cells were stimulated with high ome-
prazole concentrations (300 μM) for 3h, 18h, 24h and/or 48h, and with
low concentrations (15, 20 and 30 μM) for 7 days. Ferrostatin-1 (Fer-1,
Santa Cruz Biotechnology, Santa Cruz, CA) was used at 40 μM,
Necrostatin-1 (Nec-1, Sigma-Aldrich, St. Louis, MO) at 30 μM, z-VAD-
fmk (Bachem, Bubendorf, Switzerland) at 100 μM, and N-acetyl-cy-
steine (NAC, Sigma-Aldrich) at 1 mM concentrations, based on prior
dose response-studies and experience inhibiting tubular cell death
triggered by different stimuli [7]. 3-methyladenine (3-MA, Sigma-Al-
drich) was resuspended at 100 mM in distilled H2O. Staurosporine at
500 nM (Sigma-Aldrich) was used as positive control for apoptosis and
H2O2 (0.4 mM) as positive control for reactive oxygen species (ROS)
production. Peptide BclxL-BH4 (Merck, Darmstadt, Germany) was used
at concentrations based on previous experience with the drug in cul-
tured tubular cells [27].
2.2. Assessment of cell death
Cell viability was estimated using the 3-[4,5-dimethylthiazol-2-yI]-
2,5 diphenyltetrazolium bromide (MTT, Sigma-Aldrich) colorimetric
assay. Following stimulation, culture medium was removed, and cells
were incubated with 0.5 mg/mL MTT in PBS for 1h at 37 °C. The re-
sulting formazan crystals were dried and dissolved in DMSO.
Absorbance (indicative of cell viability) was measured at 570 nm using
a plate reader (TECAN infinite F200).
For assessment of cell death by annexin V/7-amino-actinomycin D
(7-AAD) staining, 5 × 105 cells were washed with ice-cold PBS, re-
suspended in 100 μl binding buffer, and stained with 2.5 μl PE-Annexin
V and 2.5 μl 7-AAD for 15 min at 37 °C in the dark. Then, 400 μl binding
buffer was added just before flow cytometry. Cells were analyzed using
FACS Canto cytometer and FACS Diva Software (BD Biosciences, Eysins,
Switzerland). Early and late cell death was evaluated on PE fluores-
cence (Annexin V) versus PerCP (7-AAD) plots. Cells stained only with
annexin V were considered early cell death; cells stained with both
annexin V and 7-AAD were considered late cell death or necrosis.
Cytotoxicity was assessed by the release of lactate dehydrogenase
(LDH) using the Cytotoxicity Detection Kit PLUS (LDH) according to the
manufacturer's instructions (Roche Science, Penzberg, Germany).
Fluorescence was recorded using a plate reader (TECAN infinite F200).
Nuclear morphology was assessed in formalin-fixed cells stained
with DAPI (Sigma-Aldrich) and observed with fluorescence microscopy
(Nikon E600). Cell morphology was further examined by transmission
electron microscopy (TEM) in a Jeol Jem1010 (100Kv) microscope.
Cells were fixed in 4% formaldehyde/2% glutaraldehyde in PBS, de-
hydrated and embedded in Epon resin.
2.3. Western blot
Cells were homogenized in lysis buffer (50 mM TrisHCl, 150 mM
NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% Triton X-100, 0.3% NP-40, 1 mM
PMSF and 1 μg/mL pepstatin A). Protein concentration was measured
with the BCA (bicinchoninic acid) assay (Thermo Fisher, Waltham,
MA). Equal amounts of protein were loaded in 15% SDS gel, separated
by electrophoresis and transferred to PVDF membranes (polyvinylidene
difluoride, Millipore, Darmstadt, Germany). The membranes were
blocked with 5% TBS/0.5% v/v Tween-20 skim milk and incubated
with anti-caspase3 (1:1000, Cell Signaling Technology, Danvers, MA),
anti-BcLxL (1:250, Santa Cruz), anti-Bax (1:100, BD Pharmingen, San
Jose, CA), anti-LC3 (1:1000, Novus Bio, Centennial, CO) or anti-heme
oxygenase (HO-1, 1:1000, Enzo Life Technologies, Farmigdale, NY)
antibodies dissolved in 5% milk PBS/Tween for 1h at room tempera-
ture. They were then washed with TBS/Tween and incubated with the
secondary antibodies against rabbit IgG (1:5000) or mouse IgG
(1:5000). After washing with PBS/Tween, blots were developed with
the chemiluminescence method (ECL; Thermo Fisher) and probed with
mouse monoclonal anti–alpha-tubulin antibody (1:10000, Sigma-
Aldrich). Levels of expression were corrected for minor differences in
loading.
2.4. RNA extraction and real-time polymerase chain reaction
Total RNA was extracted by the TRI Reagent method (Invitrogen,
Thermo Fisher) and 1 μg RNA was reverse transcribed with High
Capacity cDNA Archive Kit (Applied Biosystem, Thermo Fisher) [28].
Quantitative PCR was performed in a 7500 Real Time PCR System with
the Prism 7000 System SDS Software using predeveloped primers
(Thermo Fisher). RNA expression of different genes was corrected for
GAPDH.
2.5. ROS production
To assess total ROS production, 2′,7′-dichlorodihydrofluorescein
diacetate CM-H2DCFDA (Molecular Probes, Thermo Fisher) was added
3 h before flow cytometry. To assess lipid peroxidation, cells were
washed and BODIPY 581 /591 C11 (Invitrogen, Thermo Fisher) was
added for 1h before flow cytometry. After staining, cells were trypsi-
nized, washed and transferred to FACS tubes in RPMI containing 10%
FBS. Mitochondrial ROS was measured with MitoSOX red mitochon-
drial superoxide indicator (Invitrogen, Thermo Fisher). After different
treatments cells were incubated with 2.5 μM MitoSOX for 10 min at
37 °C and then fluorescence was measured at 510/580 (Ex/Em) (Spire
Multilabel Reader, PerkinElmer, Waltham, MA).
2.6. NADPH activity
NADPH activity was measured by the lucigenin chemiluminescence
assay as described [29]. Renal cell homogenates in 50 mmol/L phos-
phate buffer containing 0.01 mmol/L EDTA, 0.32 mol/L sucrose and
0.1% protease inhibitor cocktail were transferred to Röhren tubes and
then 5 μmol/L lucigenin and 100 μmol/L NADPH (Sigma-Aldrich) were
added. Chemiluminiscence was measured with a luminometer (Bert-
hold Technologies, Bad Wildbad, Germany) by counting the photon
emission at 10-s intervals over 5–10 min and values were normalized
over non-omeprazole stimulated tubular cells.
M. Fontecha-Barriuso, et al. Redox Biology 32 (2020) 101464
2
2.7. Clonogenic assays
Cells were pre-treated with NAC for 1h, and then stimulated with
omeprazole. After 48h, cells were detached with trypsin-EDTA, seeded
in Petri dishes and cultured in 10% FBS RPMI 1640 for 7 days. Then,
they were fixed and stained with crystal violet. Petri dishes were pho-
tographed and cells were resuspended in ethanol: sodium citrate 1:1
(0.1 M, pH 4.2), and absorbance (indicative of colony formation) was
measured at 570 nm (TECAN infinite F200).
2.8. Assessment of lysosomal acidity
The lysosomal function of cells was assessed using a lysosomotropic
tracking dye called LysoTracker® Red DND-99 (Life Technologies,
Thermo Fisher), which accumulates in lysosomes due to proton trap-
ping [30]. Cells were scraped into culture medium, collected into sterile
polypropylene tubes and centrifuged at 500×g for 5 min at room
temperature to remove cell debris. Then LysoTracker Red (500 nM) was
added in RPMI-1640 for 30 min at 37 °C and cells were washed twice
with PBS resuspended in FACS buffer and analyzed using FACS Canto
cytometer and FACS Diva Software (BD Biosciences).
2.9. Measurement of intracellular ATP concentration
ATP levels were measured by the Luminiscente ATP Detection Assay
Kit (Abcam, Cambridge, UK) following the manufacturer's instructions.
2.10. Animal model
All procedures were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and were approved by the
animal ethics committee of IIS-FJD (PROEX 070/17). Wild-type 12-
week-old female C57BL/6 mice received 40 mg/kg/day omeprazole
(Normon, Madrid, Spain) or vehicle intraperitoneally for 10 or 28 days
(4–5 animals per group). Dosing was based on human therapeutic
dosing and its conversion to mice dosing following FDA guidelines,
based on body surface area [31,32], using the FDA dose range for
omeprazole [33] (Fig. S1). Thus, the murine dose was within the range
of the murine equivalent dose. Blood was drawn to assess serum crea-
tinine and blood urea nitrogen (BUN), and kidneys were perfused in situ
with cold saline before remove. One kidney was snap-frozen in liquid
nitrogen for RNA and protein studies and the other was fixed and
paraffin embedded for histological studies.
3. TUNEL
Terminal deoxynucleotidyl transferase-mediated dUTP nick end la-
beling (TUNEL) assay was performed in 3 μm thick sections of paraffin-
embedded tissue with the In Situ Cell Death Detection Kit, Fluorescein
(Roche Applied), according to the manufacturer's instructions.
3.1. Statistics
Results are expressed as mean ± SEM. Differences between groups
were evaluated using Q2 one-way ANOVA with Tukey's post-hoc tests
using the Prism software (Graphpad 7.04). For pairs of samples, data
were analyzed using non-parametric Mann–Whitney test. A p-value<
0.05 was considered statistically significant.
4. Results
4.1. Omeprazole induces tubular cell death
First, the effect of omeprazole on proximal tubular cell viability was
tested. Omeprazole decreased cell viability in murine tubular cells as
assessed by MTT (Fig. 1A). Moreover, omeprazole also decreases cell
viability in both immortalized (HK-2) and primary cultures (RPTEC) of
human proximal tubular cells (Fig. 1A). The effect of omeprazole was
dose-dependent and more evident at 48h than at 24h. HK-2 cells were
studied in more detail. Phase contrast imaging showed cell detachment
and morphological changes, such as vacuole formation, in response to
omeprazole (Fig. 1B, C).
The concentration (150–350 μM) of omeprazole in Fig. 1A-C is si-
milar to the concentration reported to induce tumor cell death [34].
However, the omeprazole concentration in serum of patients on ome-
prazole is lower, around 20 μM [35]. Thus, we tested the effect of lower
concentrations of omeprazole for longer times of exposure. Omeprazole
at 20 and 30 μM for 7 days also decreased cell viability as assessed by
MTT and induced cell detachment and vacuole formation (Fig. 1D, E).
4.2. Characterization of omeprazole-induced tubular cell death
Next, we characterized the lethal effect of omeprazole on tubular
cells. Cell death was assessed by annexin V/7-AAD staining (Fig. 2A).
Omeprazole increased the number of annexin V+/7-AAD+ cells in a
dose- and time-dependent manner, while the number of annexin V+/7-
AAD- cells did not change, suggesting that cell death could be mediated
by necrosis, rather than by apoptosis (Fig. 2A). The necrotic effect of
omeprazole was confirmed by cytotoxicity assay measuring the release
of LDH [36] (Fig. 2B). Furthermore, nuclear morphology, analyzed by
DAPI staining, showed irregular chromatin clumping typical of necrosis
and ultrastructural analysis by TEM showed striking vacuole formation
and plasma membrane rupture (Fig. 2C, D). Previous reports have
suggested that apoptosis could play a role in omeprazole-induced cell
death [12], although the role of caspases has not been clarified [34].
Therefore, to evaluate the role of apoptosis in omeprazole-induced
tubular cell death, we tested caspase activation. A weak cleaved caspase
3 band was detected by Western blot in tubular cells stimulated with
omeprazole, but levels were lower than in cells stimulated with staur-
osporine, a positive control of apoptosis [37] (Fig. S2A). Moreover, the
pan-caspase inhibitor zVAD did not prevent omeprazole-induced cell
death (Fig. S2B, C). In recent years, new pathways of regulated necrosis,
such as necroptosis or ferroptosis, have been shown to contribute to
kidney disease [9,38], thus we tested their contribution to omeprazole-
induced tubular cell death. Pre-treatment with Necrostatin-1 (Nec-1) or
Ferrostatin-1 (Fer-1), at concentrations previously shown to prevent
necroptosis and ferroptosis respectively in tubular cells, was unable to
prevent omeprazole-induced cell death/loss of cell viability (Fig. S2B,
C).
4.3. Omeprazole-induced cell death is associated to increased ROS
production
Based on a previous report of the association of omeprazole cyto-
toxicity with oxidative stress [12], we analyzed ROS production in HK-
2 cells stimulated with omeprazole. Omeprazole 300 μM induced a
strong and early increase in ROS production as assessed by CM-
H2DCFDA staining and flow cytometry (Fig. 3A). Moreover, lower
concentrations of omeprazole, similar to those found in the circulation
of patients on omeprazole, also promoted a strong ROS production
(Fig. 3B). The mitochondria and NADPH oxidase are the major sources
of intracellular ROS, so we analyzed their possible involvement in
driving omeprazole-induced ROS accumulation. We measured mi-
tochondrial ROS production by MitoSOX staining, observing that
omeprazole promotes mitochondrial ROS (Fig. 3C). In addition, we
observed that omeprazole increased NADPH oxidase activity but this
followed the increase in ROS production, suggesting that NADPH oxi-
dase activity is not the initial or main driver of oxidative stress induced
by omeprazole (Fig. 3D). Moreover, we observed by BODIPY staining
and flow cytometry that increased ROS production was followed by
lipid peroxidation at later time points (Fig. 3E).
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4.4. NAC prevents omeprazole-induced cell-death
Next, we tested the effect of the common ROS scavenger N-acetyl-
cysteine (NAC) over oxidative stress and cell death induced by ome-
prazole in tubular cells. NAC prevented total and mitochondrial ROS
production and lipid peroxidation induced by omeprazole (Fig. 4A-C).
Moreover, NAC prevented cell death induced by omeprazole as assessed
by LDH release and by Annexin V/7-AAD staining, and also prevented
cell detachment and vacuole formation (Fig. 4D-F). In addition, clo-
nogenic assays showed that cells exposed to omeprazole are unable to
form colonies, but NAC reversed the decreased clonogenic survival, an
observation consistent with increased cell survival (Fig. S3). Altogether,
these results suggest that omeprazole-induced tubular cell death is in-
itiated by a strong oxidative stress that leads to lipid peroxidation. Since
lipid peroxidation and mitochondrial stress may trigger to other types
of cell death such as ferroptosis or apoptosis, we explored the in-
volvement of these forms of cell death in response to the initial wave of
ROS production. To test this hypothesis, we pre-treated the cells with a
combination of NAC and zVAD or Nec-1 or Fer-1, and we observed that
protection from cell death was increased when NAC was combined with
zVAD or Fer-1 (Fig. 4G).
Fig. 1. Omeprazole induces cell death of both human and murine tubular cells. A) Murine (MCT) and human (HK-2 and RPTEC) tubular cells were exposed to
different concentrations of omeprazole for 24h and 48h and cell viability was assessed by the MTT assay. Mean ± SD of three experiments *p < 0.05 vs vehicle;
**p < 0.01 vs control; ***p < 0.001 vs control. B) Time-course of omeprazole-induced cell death in HK-2 cells stimulated with 300 μM omeprazole. Mean ± SD of
three experiments ***p < 0.001 vs control. C) Phase contrast imaging of HK-2 cells stimulated with omeprazole. Magnification x200 (scale 100 μm) and detail x400
(scale 50 μm). Representative images of three experiments. D, E) HK-2 cells stimulated with low dose omeprazole for 7 days. (D) Cell viability Mean ± SD of five
independent experiment; *p < 0.05 vs control; ***p < 0.001 vs control. (E) Representative images of three experiments. Magnification x200 (scale 100 μm) and
detail x400 (scale 50 μm).
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4.5. Omeprazole induces lysosomal alkalization and reduces ATP levels
Omeprazole alters intracellular pH in tumor cells. Thus, we ana-
lyzed the effect of omeprazole on lysosomal pH by detecting the
fluorescence intensity of LysoTracker® Red DND-99. We observed that
omeprazole decreased the fluorescence intensity in HK-2 cells (Fig. 5A),
indicating an increase in lysosomal pH. Moreover, lysosomal alkaliza-
tion was prevented with NAC (Fig. 5B), suggesting that ROS production
is an early event upstream of the altered intracellular pH gradients.
Next, we assessed intracellular ATP levels. In contrast breast cancer
cells, where PPIs increased ATP levels and this was ascribed to inhibi-
tion of V-ATPase activity [39], we observed that omeprazole dramati-
cally decreases intracellular ATP levels in tubular cells (Fig. 5C). In-
tracellular ATP decreased at early times points and, as the increased
ROS levels, it was already observed at 1h (Fig. 5C), suggesting that
together with oxidative stress it may a driver of cell death. In this re-
gard, the decrease in ATP production was little responsive to NAC
(Fig. 5D).
Fig. 2. Omeprazole-induced cell death has features of necrosis. A) HK-2 cells were exposed to omeprazole for 24h, stained with annexin V/7-AAD and analyzed
by flow cytometry. Omeprazole increased annexin V+/7-AAD+ cells but not annexin V+/7-AAD- cells. Mean ± SD of three independent experiments. B) Time-
course of omeprazole-induced necrosis measured by LDH release. Mean ± SD of three independent experiment; **p < 0.01 vs control; ***p < 0.001 vs control. C)
DAPI-stained cells exposed to 300 μM omeprazole for 24h disclosed irregular chromatin clumping suggestive of necrosis (arrow). Representative images of three
independent experiments. Magnification x200 (scale 100 μm) and detail x400 (scale 50 μm). D) TEM of cells exposed to 300 μM omeprazole for 24 and 48h disclosed
cells with a typical necrotic morphology, characterized by membrane rupture (add arrowhead) and extensive vacuolization (add arrow). Magnification x6000 and
detail x30000.
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4.6. Omeprazole promotes expression of BclxL and autophagy in HK-2 cells
BclxL and Bax are members of Bcl-2 family proteins which regulate
cell death at the mitochondrial level. Since omeprazole induced mi-
tochondrial oxidative stress, we measured the BclxL/Bax ratio, obser-
ving that omeprazole upregulates the antiapoptotic protein BclxL while
the levels of proapoptotic Bax were weakly downregulated, leading to
an increased BclxL/Bax ratio (Fig. 6A, B). This suggests that, similar to
the response to other nephrotoxic agents [8], the increased BclxL ex-
pression may be an adaptive response, which is unable to prevent cell
death. However, the BclxL mimetic BclxL-BH4 [27] was not protective
(Fig. 6C).
Omeprazole also promotes autophagy as a survival mechanism in
melanoma cells. Now, we observed that omeprazole may induce au-
tophagy in HK-2 cells since it increased the LC3II/LC3I ratio at 48h as
assessed by LC3 Western blot (Fig. 6D). However, the autophagy in-
hibitor 3-methyladenine (3-MA) reduced LC3II/LC3I ratio (Fig. 6D), but
did not significantly modify the lethal effect of omeprazole, suggesting
that autophagy is not a key pathway in omeprazole-induced cell death
(Fig. 6E).
4.7. Omeprazole-induced cell death may be modified by environmental
factors
In routine clinical practice, omeprazole is frequently prescribed in
association with other potentially nephrotoxic drugs, including oral
anticoagulants. These drugs have been associated with a specific form
of kidney injury termed anticoagulant associated nephropathy char-
acterized by recurrent hematuria and proximal tubular cell iron over-
load [40–42]. Thus, we explored the interaction between iron overload
and omeprazole. Sublethal iron overloading resulted in a higher lethal
effect of omeprazole in tubular cells (Fig. S4).
Fig. 3. Omeprazole induced ROS production. HK-2 cells were stimulated with 300 μM omeprazole (A, C-E) or lower concentrations (B) for different time periods.
A, B) ROS production was assessed by CM-H2DCFDA staining and flow cytometry. Mean ± SD of four or three independent experiments. *p < 0.05 vs control;
**p < 0.01 vs control; ***p < 0.001 vs control. C) Mitochondrial ROS production assessed by MitoSOX staining and flow cytometry. Mean ± SD of five
independent experiments. *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control. D) NADPH oxidase activity was assessed by lucigenin che-
miluminescence assay. Mean ± SD of three independent experiments. *p < 0.05 vs control. E) Lipid peroxidation was assessed using the redox-sensitive dye
BODIPY 581/591 C11. Mean ± SD of three independent experiments. *p < 0.05 vs control; **p < 0.01 vs control.
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4.8. Omeprazole induces renal injury in vivo
To explore the in vivo relevance of the cell culture results, we tested
the effect of omeprazole in vivo. Omeprazole was injected daily to
healthy mice for 10 or 28 days. While omeprazole did not increase
serum creatinine or urea, which is consistent with its well-known lack
of severe nephrotoxic potential, as is evident from its widespread
clinical use, kidney expression of the tubular cell injury marker NGAL
was increased (Fig. 7A, B), and an increased tubular cell death was
observed by TUNEL staining (Fig. 7C). In addition, omeprazole in-
creased the expression of the oxidative stress marker Heme-Oxygenase-
1 (HO-1) at the mRNA and protein levels (Fig. 7D, E). These results
support the hypothesis that omeprazole has nephrotoxic potential by
promoting cell death and are consistent with its clinical association
with CKD. However, the nephrotoxic potential is low and in mice was
subclinical.
5. Discussion
Recent clinical data point to a subtle nephrotoxic effect of ome-
prazole, but the cellular and molecular mechanisms are unknown. Now,
we have observed that omeprazole directly induces cell death in cul-
tured tubular renal cells in vivo e in vitro through the generation of
oxidative stress-induced cell death. Overall the data are consistent with
Fig. 4. Omeprazole-induced cell death is ROS-dependent. HK-2 cells pretreated with 1 mM NAC for 1h and stimulated with 300 μM omeprazole for the indicated
periods of time. A-C) ROS production, mitochondrial ROS and lipid peroxidation were measured at 24h. Mean ± SD of three of four independent experiments.
**p < 0.01 vs control; ***p < 0.001 vs control; ##p < 0.01 vs omeprazole; ###p < 0.001 vs omeprazole. D) Necrosis was assessed by the LDH release assay.
Mean ± SD of 4 independent experiments. ***p < 0.001 vs control; ##p < 0.01 vs omeprazole; ###p < 0.001 vs omeprazole. E) Cell death was measured by
flow cytometry of annexin V/7-AAD stained cells. Mean ± SD of three independent experiments. **p < 0.01 vs control; #p < 0.05 vs omeprazole. F) Phase
contrast (x400, scale 50 μm) and TEM (x6000) images showing NAC protection from omeprazole-induced toxicity at 24 h. Representative images of three in-
dependent experiments. G) HK-2 cells pretreated with NAC alone or in combination with zVAD, Nec-1 or Fer-1 for 1h and stimulated with 300 μM omeprazole for
48h. Cell viability was assessed by the MTT assay. Mean ± SD of five independent experiments. **p < 0.01 vs omeprazole + NAC; ***p < 0.001 vs
omeprazole + NAC.
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omeprazole induced mitochondrial injury resulting in decreased ATP
availability and increased oxidative stress, the latter driving cell death.
Furthermore, these experiments have identified NAC as a potential
nephroprotective drug in this context.
Omeprazole is one of the most widely used PPIs and prescription has
increased significantly in recent years. However, in up to 40% of cases,
PPI prescription does not follow the indications acknowledged by
health authorities and, in some cases treatment is continued long term,
regardless of clinical indication [43]. This is an economic burden to
healthcare systems as well as a risky practice, since long-term use of
PPIs has been associated with different adverse effects including AKI
and CKD [44]. Indeed, PPIs are frequently included in lists of drugs that
are potential targets of deprescription strategies. When PPIs are ap-
propriately prescribed, their benefits are likely to compensate their
risks [45]. However, a false sense of safety may have contributed to PPI
abuse.
The first case of omeprazole-induced AIN was published in 1999
[46], and by 2009 there were 114 reported cases of PPIs-induced AIN
[16]. PPIs were a major cause of AIN in the elderly [18]. More recent
studies have identified PPIs as a risk factor for CKD, and higher doses of
PPIs were associated with a higher risk of CKD [20–23]. Moreover, a
prospective study concluded that prophylaxis with omeprazole may
contribute to renal impairment in males [24]. Renal biopsies of ome-
prazole-induced AIN showed acute tubulitis and tubular infiltrates,
while glomeruli were not injured [47]. While the molecular
mechanisms of injury may differ between AIN and CKD, this data
suggest that tubular cells may be involved in at least some forms of
omeprazole nephrotoxicity. Furthermore, the V-ATPase, a cellular
target of PPIs, has key functions in tubular cells. Mutations in genes
encoding the distal tubular V-ATPase cause genetic forms of distal
tubular acidosis [48]. More recently dysfunction of the proximal tub-
ular V-ATPase, which has a different subunit composition from distal
tubular V-ATPase, has been involved in Dent's disease, characterized by
proximal tubular cell injury and progressive CKD [49]. Understanding
the molecular and cellular mechanism of nephrotoxicity would support
the biological plausibility of the PPI-kidney injury link and help de-
velop preventive and therapeutic strategies.
We have now identified for the first time and characterized the
molecular mechanisms of omeprazole-induced oxidative stress and cell
death in tubular renal cells. Omeprazole-induced cell death had pre-
viously been observed in cancer cells and leukocytes [12–14,34,50].
However, the cell death pathways activated by omeprazole may be cell
type-dependent. In normal human lymphocytes omeprazole-induced
cell death is mediated by apoptosis, while in human B-cell tumors cell
death is caspase-independent [12,50]. We have observed that ome-
prazole promotes mild caspase-3 activation in tubular cells, but apop-
tosis did not trigger eventual cell death, since the pan-caspase inhibitor
zVAD was not protective. Additionally, neither necroptosis nor ferrop-
tosis mediate cell death induced by omeprazole. However, morpholo-
gical and functional characterization of tubular cell death induced by
Fig. 5. Omeprazole induces lysosomal alkalization through ROS production. A, C) HK-2 cells were stimulated with 300 μM omeprazole and lysosomal pH was
measured by LysoTracker Red DND-99 (A) and intracellular ATP levels were measured with a Luminiscente ATP detection assay (C). B, D) Pre-treatment with NAC
preserves lysosomal pH but it does not recover intracellular ATP levels in presence of omeprazole. A-D) Mean ± SD of three or five independent experiments.
*p < 0.05 vs control, ***p < 0.001 vs control; ###p < 0.001 vs omeprazole. (For interpretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.)
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omeprazole showed features of necrosis such as early membrane per-
meabilization as assessed by Annexin V/7-AAD staining, LDH release,
irregular chromatin condensation and presence of vacuoles. Omepra-
zole toxicity had been linked to oxidative stress in non-renal cells
[12,14,51]. In this regard, we have observed that omeprazole promotes
a strong oxidative stress which was prevented by NAC suggesting that
the main source of ROS is cytosolic. NOX4, a member of the NADPH
oxidase, is the main source of cytosolic ROS in kidneys and contributes
to different forms of renal disease [52]. In melanoma cells omeprazole-
induced oxidative stress is mediated by NADPH oxidase [14]. However,
omeprazole-induced NADPH oxidase activation in tubular cells oc-
curred later that ROS production, thus, further studies are necessary to
confirm the role of NOX4 in oxidative stress induced by omeprazole in
tubular cells. In addition, omeprazole also induces mitochondrial ROS
Fig. 6. Omeprazole increased the BclxL/Bax ratio and autophagy in HK-2 cells. A) HK-2 cells were stimulated with 300 μM omeprazole and Bax and BclxL
protein expression was assessed by Western blot. Representative Bax and BclxL Western blot. Mean ± SD of three of four independent experiments. *p < 0.05 vs
control. B) BclxL/Bax ratio. Mean ± SD of three independent experiments. *p < 0.05 vs control. C) Cells were pretreated with BclxL-BH4 peptide 1 h before
omeprazole stimulation, and cell viability was assessed by MTT. Mean ± SD of three independent experiments. **p < 0.05 vs control. D) Representative Western
blot and quantification of LC3II/LC3I ratio in HK-2 cells pretreated with different doses of 3-MA for 1h and stimulated with 300 μM omeprazole for 24 or 48h.
Mean ± SD of three independent experiments. *p < 0.05 vs control; #p < 0.05 vs 3-MA 0 μM. E) Cell viability and (F) cytotoxicity of HK-2 cells pretreated with
different doses of 3-MA for 1 h and stimulated with 300 μM omeprazole for 48 h. Mean ± SD of four or three independent experiments. ***p < 0.001 vs control.
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production at early time-points, which together with a dramatic de-
crease in ATP production may point to a key role of mitochondrial in-
jury. V-ATPases are targets of omeprazole, and this or the decrease in
ATP availability can explain the lysosomal alkalization observed in HK-
2 cells. However, lysosomal alkalization seems to be a consequence of
ROS production since it was prevented by NAC.
Different pathways of cell death potentially involved in renal injury
include apoptosis, regulated necrosis (e,g, necroptosis or ferroptosis), as
well as other forms of necrotic cell death that do not easily fit into one
of these categories, like that induced by deferasirox in proximal tubular
cells leading to deferasirox nephrotoxicity [8,53]. However, neither the
RIPK1 specific inhibitor Nec-1 that prevents bona fide necroptosis in
tubular cells and the kidney [7] nor the ferroptosis inhibitor Fer-1 did,
by themselves, prevent omeprazole-induced cell death. This suggests
that omeprazole-induced cell death, despite being necrotic in nature,
according to microscopical features, annexin V/7-AAD staining and
LDH release, was not mediated by the two main forms of regulated
necrosis (necroptosis and ferroptosis). However, our data are consistent
with a model in which a strong oxidative stress will trigger necrosis, but
a reduction of oxidative stress, as in the presence of NAC, will rescue
some cells from this necrotic cell death, but additional cell death
pathways may be then activated and contribute to residual NAC-re-
sistant cell death. Thus, in presence of NAC, both apoptosis and regu-
lated necrosis through ferroptosis appear to be recruited, since the
combination of NAC with Fer-1 or the pan-caspase inhibitor zVAD of-
fered additional protection. In this regard, the conversion from one
form of cell death to another in presence of cell death inhibitors is not
unusual. As an example, a cytokine cocktail composed of TWEAK, TNF
and interferon-gamma elicits apoptosis in tubular cells, but when
apoptosis is inhibited by zVAD, necroptotic cell death sensitive to Nec-1
is triggered and the number of dying cells increases [9,37].
We also observed an increased mitochondrial stress under
Fig. 7. Omeprazole induces renal injury in vivo. Mice were injected daily with 40 mg/kg omeprazole for 10 or 28 days. A) Serum creatinine and BUN levels. B)
Kidney mRNA expression of the renal injury marker NGAL. C) Cell death quantified by TUNEL staining. Representative images. Confocal microscopy. Original
magnification x400 (scale 20 μm). D) mRNA expression of Hemo-oxygenase-1 (HO-1) assessed by RT-PCR. E) Protein levels of HO-1 assessed by Western blot at 28
days of omeprazole treatment. Quantification and representative image. A-E) Mean ± SEM of 4–5 animals per group. *p < 0.05 vs control; **p < 0.01 vs control;
***p < 0.001 vs control.
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omeprazole, as well as increased levels of the anti-apoptotic protein
BclxL. Increased expression of BclxL has been also observed in ne-
phrotoxic AKI and thought to represent an adaptive nephroprotective
mechanism [54]. However, these higher BclxL levels or even higher
levels following treatment with a BclxL mimetic were unable to prevent
omeprazole nephrotoxicity. Likewise, autophagy can sometimes be
activated as protective mechanism and, in this case, its inhibitor 3-MA
may amplify the lethal effect, as observed for melanoma cells, where
autophagy is an adaptive survival mechanism against drug-induced
cytotoxicity including PPI [14]. However, for tubular cells, no statisti-
cally significant impact of 3-MA was observed.
Omeprazole induced cell death in both murine and human tubular
cells at concentrations found in serum of patients, supporting biological
plausibility. In this regard, in vivo omeprazole also caused tubular cell
injury, although only sensitive markers of kidney injury were altered,
consistent with a low nephrotoxic potential and with clinical practice
experience.
This study has several limitations that should be addressed in fur-
ther studies. We have only explored the effect of omeprazole, but more
PPIs are used in the clinic. Further studies should characterize the ne-
phrotoxic potential of different PPIs. Furthermore, the in vivo dose of
omeprazole was high. However, the in vivo data should be considered
proof-of-concept and they were generated in young healthy mice, while
PPIs are frequently used in elderly individuals with multiple
Fig. 8. Current working hypothesis. Omeprazole
promotes necrotic cell death in cultured proximal
tubular cells. This is associated to an early decrease
in ATP levels and an early increase in mitochon-
drial ROS production, suggesting mitochondrial
injury. ROS are instrumental in promoting necrotic
cell death, which is inhibited by N-acetyl-cysteine
(NAC). However, interventions over apoptosis,
ferroptosis and necroptosis were not protective.
Omeprazole-induced necrosis may lead to the re-
lease of cell debris that may facilitate the devel-
opment of an immune response underlying the
observations of acute tubulointerstitial nephritis
cases reported in omeprazole-treated patients.
Additionally, omeprazole caused subclinical ne-
phrotoxicity in mice. This is consistent with the
low nephrotoxic potential of omeprazole in hu-
mans. In this regard, omeprazole nephrotoxicity
may be increased by additional environmental
factors, including comorbidities and concomitant
medications. Among them, a frequent association is
oral anticoagulants that may lead to proximal
tubular cell iron overload. In cultured cells, iron
overload facilitated omeprazole nephrotoxicity.
The combination of these additional factors may
explain why glomerular filtration rate is lost at a
faster rate in patients on chronic omeprazole
therapy.
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comorbidities and using multiple prescription and over-the-counter
drugs with nephrotoxic potential, including non-steroidal anti-in-
flammatory agents, paracetamol and anticoagulants, among others
[55–57]. Additionally, omeprazole has been used at doses of up to
360 mg/day [33] and liver metabolism is saturable and decreases with
repeating dosing, potentially leading to higher serum concentrations
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/
019810s096lbl.pdf; accessed 23 December 2019).
Despite these limitations, this study strongly supports a direct toxic
effect of omeprazole on tubular cells, and this was observed in cultured
immortalized murine and human cells, and in primary cultures of
human cells at clinically relevant concentrations and in vivo in mice. In
this regard, anticoagulant-associated nephropathy is characterized by
hematuria and proximal tubular cell iron overload [40,42] and antic-
oagulated elderly individuals are frequently prescribed PPIs. Cell cul-
ture data suggest that the combination of omeprazole and iron overload
may increase omeprazole nephrotoxicity. Additional comorbidities
might impact omeprazole nephrotoxicity. Thus, in liver disease, plasma
clearance of omeprazole is decreased by approximately 10-fold
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/
019810s096lbl.pdf; accessed 23 December 2019).
In conclusion, we have shown for the first time, that omeprazole has
a direct lethal effect over human tubular cells and have characterized
some molecular pathways involved (Fig. 8). Omeprazole-induced cell
death is caspase-independent, and ferroptosis and necroptosis are not
involved. However, oxidative stress was evident and an antioxidant was
protective. These findings lend biological plausibility to the epidemio-
logical data linking PPIs to CKD and provide a basic framework for the
development of less toxic PPIs as well as novel preventive and ther-
apeutic strategies.
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